Financial Post EN

For the First Time, Ferring Reports Revenue of Over €2.5 Billion in 2025

Ferring’s total revenues for 2025 exceeded €2.5 billion, an increase of 10% from 2024, mainly driven by our flagship product Menopur® Continued ramp-up in the US for Adstiladrin®, our novel gene-based therapy for bladder cancer, confirming its position as Ferring’s second major growth driver Commitment to sustainability demonstrated by SBTi approval of our targets to […]

Mar 10, 2026 &03021010202631; 09:02 UTC financialpost.com Trending 4/5

Read original on financialpost.com ↗

↗

Positive for markets

Sentiment score: +75/100

Moderate impact Short-term (days)

WHAT THIS MEANS

Ferring Pharmaceuticals reported 2025 revenues exceeding €2.5 billion, representing 10% year-over-year growth driven by flagship product Menopur® and continued expansion of Adstiladrin® in the US market. The company demonstrates strong operational momentum with dual growth drivers and sustainability commitments, positioning it favorably for continued expansion.

AI CONFIDENCE

85% Very high

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

FERR

FERRStock

Expected to rise

Strong revenue growth of 10% YoY with €2.5B+ milestone achieved; dual growth drivers (Menopur and Adstiladrin) demonstrate diversified revenue streams and market expansion success

↑

EU→.PA

EU→.PAIndex

Expected to rise

European pharmaceutical sector benefits from positive earnings report from major player; demonstrates sector resilience and growth potential

↑

Euro Stoxx 50

^STOXX50EIndex

Expected to rise

Positive sentiment from European healthcare/pharma segment contributes to broader European equity index performance

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Consider accumulating positions in European pharmaceutical equities, particularly Ferring if publicly traded or comparable peers. The 10% growth rate with dual growth drivers suggests sustainable momentum; monitor Adstiladrin® US adoption rates as key performance indicator for 2026 guidance.

KEY SIGNALS

Double-digit revenue growth (10% YoY)Flagship product Menopur® driving primary growthAdstiladrin® (gene therapy) gaining US market traction as secondary growth driverSBTi sustainability target approval indicates ESG credibility€2.5B revenue milestone represents significant scale achievement

SECTORS INVOLVED

PharmaceuticalsHealthcareBiotechnology

Analysis generated on Mar 11, 2026 at 03:40 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Financial Post. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

For the First Time, Ferring Reports Revenue of Over €2.5 Billion in 2025

RELATED INTELLIGENCE